期刊
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
卷 29, 期 2, 页码 216-228出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2016.08.020
关键词
Waldenstrom macroglobulinemia; MYD88; Deubiquitinating enzymes; Ibrutinib; Proteasome
类别
资金
- Daniel Foundation of Alabama
- University of Iowa/Mayo Clinic Lymphoma SPORE [P50 CA097274]
- Mayo Clinic Multiple Myeloma SPORE [P50 CA186781-01A1]
- Henry J. Predolin Foundation
Understanding of molecular mechanisms that drive Waldenstrom macroglobulinemia (WM) cell survival are rapidly evolving. This review briefly highlights emerging WM-relevant targets; for which therapeutic strategies are currently being investigated in preclinical and clinical studies. With the discovery of MYD88(L265P) signaling and remarkable activity of ibrutinib in WM, other targets within the B-cell receptor pathway are now being focused on for therapeutic intervention. Additional targets which play a role in WM cell survival include TLR7, 8 and 9, proteasome-associated deubiquitinating enzymes (USP14 and UCHL5), XPO1/CRM1 and AURKA. New drugs for established targets are also discussed. Lastly, we spotlight 3 highly innovative WM-specific therapies: MYD88 peptide inhibitors, MYD88(L265P)-directed immune activation and CD19-directed chimeric antigen receptor T-cell therapy, which are in various stages of development. Indeed, treatment of WM is poised to undergo a paradigm shift in the coming years towards highly disease-driven and more personalized therapeutic modalities with curative intent. (C) 2016 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据